Literature DB >> 20221880

The contribution of high density lipoprotein apolipoproteins and derivatives to serum paraoxonase-1 activity and function.

Richard W James1, Sara P Deakin.   

Abstract

High density lipoproteins (HDL) not only provide a serum transport vector for paraoxonase-1 (PON1) but also contribute to enzyme activity, stability and, consequently, function. The contribution of the apolipoprotein (apo) components of HDL to overall PON1 activity and function is not clearly established. ApoAI appears of major importance in defining serum PON1 activity and stability, but in the context of an interaction with the phospholipid fraction of HDL. This may involve a role in establishing the architecture of the HDL particle that optimally integrates the PON1 peptide. As the second, major structural peptide of HDL, apoAII may accomplish a similar role. These apolipoproteins, together with others associated with HDL, may also exert a more indirect influence on PON1 function by sequestering oxidised lipids that could compromise enzyme activity. The latter has been exploited therapeutically to give rise to apolipoprotein mimetic peptides that may be useful in limiting oxidative stress within the lipoprotein system, thus permitting PON1 activity to be maximally expressed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20221880     DOI: 10.1007/978-1-60761-350-3_16

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial.

Authors:  Joana R Batuca; Marta C Amaral; Catarina Favas; Filipe S Paula; Paul R J Ames; Ana L Papoila; José Delgado Alves
Journal:  Br J Clin Pharmacol       Date:  2017-01-18       Impact factor: 4.335

2.  HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer.

Authors:  Feng Su; Victor Grijalva; Kaveh Navab; Ekambaram Ganapathy; David Meriwether; Satoshi Imaizumi; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Mol Cancer Ther       Date:  2012-03-13       Impact factor: 6.261

3.  Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency.

Authors:  Monica Gomaraschi; Alice Ossoli; Samuela Castelnuovo; Sara Simonelli; Chiara Pavanello; Gloria Balzarotti; Marcello Arca; Alessia Di Costanzo; Tiziana Sampietro; Gaetano Vaudo; Damiano Baldassarre; Fabrizio Veglia; Guido Franceschini; Laura Calabresi
Journal:  J Lipid Res       Date:  2017-03-28       Impact factor: 5.922

4.  Estradiol enhances cell-associated paraoxonase 1 (PON1) activity in vitro without altering PON1 expression.

Authors:  Syed Ahmad; John E Scott
Journal:  Biochem Biophys Res Commun       Date:  2010-05-27       Impact factor: 3.575

5.  Lactonase activity and status of paraoxonase 1 and oxidative stress in neonates of women with gestational diabetes mellitus.

Authors:  Mi Zhou; Xing-Hui Liu; Qing-Qing Liu; Meng Chen; Huai Bai; Chen-Yu Jiang; Lin-Bo Guan; Ping Fan
Journal:  Pediatr Res       Date:  2020-06-22       Impact factor: 3.756

6.  Association of elevated apoA-I glycation and reduced HDL-associated paraoxonase1, 3 activity, and their interaction with angiographic severity of coronary artery disease in patients with type 2 diabetes mellitus.

Authors:  Ying Shen; Feng Hua Ding; Jia Teng Sun; Li Jin Pu; Rui Yan Zhang; Qi Zhang; Qiu Jing Chen; Wei Feng Shen; Lin Lu
Journal:  Cardiovasc Diabetol       Date:  2015-05-13       Impact factor: 9.951

7.  Aerobic training modulates the effects of exercise-induced oxidative stress on PON1 activity: a preliminary study.

Authors:  Aneta Otocka-Kmiecik; Marek Lewandowski; Urszula Szkudlarek; Dariusz Nowak; Monika Orlowska-Majdak
Journal:  ScientificWorldJournal       Date:  2014-10-14

8.  Lactonase Activity, Status, and Genetic Variations of Paraoxonase 1 in Women with Gestational Diabetes Mellitus.

Authors:  Mi Zhou; Xing-Hui Liu; Qing-Qing Liu; Meng Chen; Huai Bai; Lin-Bo Guan; Ping Fan
Journal:  J Diabetes Res       Date:  2020-02-03       Impact factor: 4.011

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.